(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Health Care Sector

Ballard Inks $25M Deal With Broad-Ocean For Fuel Cell Engine Manufacture & Sales in China

February 16th, 2017

VANCOUVER, CANADA and ZHONGSHAN, CHINA / CRWE PRESS RELEASE / February 16, 2017 - Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) today announced that it has signed a definitive agreement relating to technology transfer, licensing and supply arr. Read more

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

Kitov Provides Further Update on Formal Investigation by Israeli Securities Authority

February 09th, 2017

Tel Aviv, Israel / CRWE PRESS RELEASE / February 9, 2017 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, in response to requests made by the NASDAQ Stock Market, today provided a further upda. Read more

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

January 30th, 2017

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass. / CRWE PRESS RELEASE / January 30, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharma. Read more

Walgreens Boots Alliance and Rite Aid Enter into Amendment and Extension to Merger Agreement

January 30th, 2017

Deerfield, Ill. and Camp Hill, Pa. / CRWE PRESS RELEASE / January 30, 2017 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Rite Aid Corporation (NYSE: RAD) today announced that they have entered into an amendment and extension of their previously . Read more

Pluristem Announces Bought Deal Offering

January 19th, 2017

Haifa, Israel / CRWE PRESS RELEASE / January 19, 2017 - Pluristem Therapeutics Inc. (NASDAQCM: PSTI, TASE: PLTR) announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC, under which the underwriter has agree. Read more

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

January 17th, 2017

* PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients * This approval joins those from the U.S. FDA and U.K. fo. Read more

Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen

January 17th, 2017

* Biogen will pay Forward a non-refundable cash fee of $1.25 billion * Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain . Read more

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

January 12th, 2017

* Top line results from the 172-patient trial to be reported in early 2018 * Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe * 14 million people in the U.S. are treate. Read more

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR as its Mutation Enrichment Platform

January 12th, 2017

Three-Year Renewable Agreement Also Includes Non-Exclusive License to ICP in Canada New Patent Has Issued Covering ICE COLD-PCR Technology in Canada OMAHA, Neb. / CRWE PRESS RELEASE / January 12, 2017 - Transgenomic, Inc. (TBIO) (NASDAQ: . Read more

NOVADAQ Announces Preliminary Unaudited Fourth Quarter 2016 Revenue and Issues 2017 Revenue Guidance

January 11th, 2017

Secures up to $60 million in financing from Midcap Financial Toronto, Ontario / CRWE PRESS RELEASE / January 10, 2017 - NOVADAQ Technologies Inc (NASDAQ:NVDQ; TSX:NDQ), the leading provider of proven comprehensive fluorescence . Read more

Load More Content